We hope to introduce new tools that can
help medical professionals guide therapy management for patients throughout
the course of treatment. "The
research being presented this week is compelling and further validates our
confidence in Aspect's ability to apply its expertise to develop new tools for
the treatment of neurological and psychiatric conditions like depression.4 percent of Aspect
equity.

Today's Conference Call
Representatives from Aspect Medical Systems and Boston Scientific and Dr.
For example, the Company may not be able to successfully develop products in
this area, achieve widespread market acceptance of its BIS monitoring
technology or to compete with new products or alternative techniques that may
be developed by others, including third-party anesthesia monitoring products
approved by the U. H&D's Pelvic Pain & Continence Rehabilitation Program is
located at 12 East 46th Street, 8th Floor in Midtown Manhattan., Somanetics Corporation
(Nasdaq: SMTS) reported net revenues of $5.0 million in the same
period of 2005. net revenues increased 44 percent to $4.00 per share.

Safe-Harbor Statement
Except for historical information contained herein, the matters discussed
in this news release, including financial guidance for fiscal year 2006,
expected U.

voluntarily clinicians

Aspect has amended its shareholder rights plan to provide that Boston
Scientific may acquire beneficial ownership of, or commence a tender offer
for, just under 29. (Nasdaq: ASPM) is a global market leader in
brain monitoring technology. In addition, any
forward -looking statements represent the Company's views only as of the date
of this press release and should not be relied upon as representing the
Company's views as of any subsequent date. Boston Scientific
wishes to caution the reader of this press release that actual results may
differ from those discussed in the forward-looking statements and may be
adversely affected by, among other things, risks associated with new product
development, clinical trials, the regulatory approval process, reimbursement
policies , commercialization of new technologies, intellectual property, and
other factors described in the Company's filings with the Securities and
Exchange Commission. These techniques create an overall positive impact on the
client's symptoms, sometimes eliminating the client's pain altogether. Somanetics also is
evaluating placing personnel in Europe to support its European distributor,
Tyco Healthcare .
Surgeons, anesthesiologists and other medical professionals can use the
information provided by the INVOS System, in conjunction with other available
information, to identify brain oxygen imbalances and take necessary corrective
action, potentially improving patient outcomes and reducing the costs of care.

SOMANETICS CORPORATION
BALANCE SHEETS

February 28, November 30,
2006 2005
ASSETS (Unaudited) (Audited)
CURRENT ASSETS:
Cash and cash equivalents $14,395,224 $13,148,237
Accounts receivable 2,968,919 3,531,740
Inventory 1 ,184,044 1,058,101
Prepaid expenses 314,427 623,303
Deferred tax asset - current 1,675,011 1,561,322
Total current assets 20,537,625 19,922,703
PROPERTY AND EQUIPMENT (at cost):
Demonstration and no capital cost
sales equipment at customers 2,040,906 1,916,655
Machinery and equipment 1,118,118 768 ,992
Furniture and fixtures 295,906 289,397
Leasehold improvements 192,615 187,135
Total 3,647,545 3,162,179
Less accumulated depreciation and
amortization (1,944,237) (1,836,438)
Net property and equipment 1,703,308 1,325,741
OTHER ASSETS:
Deferred tax asset - non-current 7,815,871 8,438,678
Other 244,412 15,000
Intangible assets, net 15,193 16,921
Total other assets 8,075,476 8,470,599
TOTAL ASSETS $30,316,409 $29,719,043

LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable $955,795 $712,796
Accrued liabilities 531,673 1,165,594
Total current liabilities 1,487,468 1,878,390
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY:
Preferred shares; authorized,
1,000,000 shares of $.01 par value; issued and
outstanding, 10,715,885 shares at
February 28, 2006 , and 10,715,885
shares at November 30, 2005 107,159 107,159
Additional paid-in capital 64,864,554 64,864,554
Accumulated deficit (36,142,772) (37,131,060)
Total shareholders' equity 28,828,941 27,840,653
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $30,316,409 $29 ,719,043

SOMANETICS CORPORATION
STATEMENTS OF OPERATIONS
(Unaudited)

For the Three-Month
Periods Ended
February 28, February 28,
2006 2005

NET REVENUES $5,753,715 $4,032,617
COST OF SALES 710,499 550,149
Gross Margin 5,043,216 3,482,468

OPERATING EXPENSES:
Research, development and engineering 178,066 95,802
Selling, general and administrative 3,507,881 2,576,136
Total operating expenses 3,685,947 2,671,938

OPERATING INCOME 1,357,269 810,530

OTHER INCOME:
Interest income 140,136 43,903
Total other income 140,136 43,903
NET INCOME BEFORE INCOME TAXES 1,497,405 854,433

INCOME TAX PROVISION (509,118) (290,507)

NET INCOME $988,287 $563,926

NET INCOME PER COMMON SHARE - BASIC $.

minder clinicians

This finding is
significant because it typically takes several weeks to determine if a
depressed patient has responded to a specific treatment, and many patients
suffer while they undergo multiple changes in therapy to identify an effective
regimen.5 million.08 per diluted share.8 million from $3.05 per diluted
share in the first quarter of 2005.
"Our financial results for the first quarter were in line with our
expectations , including strong sequential growth in SomaSensor units and
seasonally lower hardware revenues," said Bruce J.

clinicians psychophysiology

We
look forward to working together with the mutual goal of introducing
innovative products that address this sizeable clinical need.m.somanetics.

subconscious neurotherapy

Boston Scientific currently owns approximately 27. It is estimated that 9.8 million.8 million for the first quarter
ended February 28, 2006, a 43 percent increase from $4.S. "The completion of our public offering
gives us the additional financial strength and flexibility to aggressively
pursue our business goals."

About Somanetics
Somanetics Corporation (Nasdaq: SMTS) develops, manufactures and markets
the INVOS(R) System , a non-invasive patient monitoring system that
continuously measures changes in the blood oxygen levels in the brain.

psychophysiology biofeedback

The significance
of this research alliance is reinforced by findings being presented at this
week's meeting of the American Psychiatric Association (APA) indicating that
Aspect 's technology may be able to help clinicians improve patient response to
antidepressant therapy and provide early identification of cognitive decline
associated with AD. To hear the replay, please dial 1-888-203-1112 (domestic),
1-719-457-0820 (international) and enter passcode: 161 4513

About Aspect Medical Systems, Inc. Aspect's BIS technology directly measures the
effects of anesthetics and sedatives on the brain.S.com.2 million women have chronic pelvic
pain and that 2 to 10% of men suffer from it.

Despite the prevalence of this condition, many are reluctant to talk about
their condition; in some cases, men and women bounce from one doctor to
another seeking an accurate diagnosis . Barrett, Somanetics'
president and chief executive officer.

Technology Advances
Adding to the INVOS System's capability to monitor changes in regional
cerebral blood oxygen saturation , in November 2005, Somanetics received FDA
510(k) clearance to market the INVOS System to monitor changes in blood oxygen
saturation in somatic, or skeletal muscle, tissue in patients with or at risk
for restricted blood flow. The call also will be archived on
the website.S.

optimal rivalry

(Nasdaq:
ASPM ) today announced a strategic alliance in which Boston Scientific will
provide Aspect $25 million to fund development of new brain monitoring
technology designed to aid the diagnosis and treatment of depression,
Alzheimer's disease (AD) and other neurological conditions.3 million patients and has been the
subject of approximately 1,800 published articles and abstracts.

In addition to offering exceptional care, H&D's Pelvic Pain specialists can
refer its clients to a range of experts -- including urologists,
psychologists, sex therapists, and pain medicine doctors. Financial Highlights
* Net revenues climbed 43 percent to $5.
Somanetics also is developing a smaller sensor for use on smaller patients
found in the pediatric ICU, as well as to support plans to launch the product
into the neonatal ICU in late 2006.

binocular neuronal

Leuchter will host a conference call 12:00 p.com.

There are a number of factors that could cause actual results to
differ materially from those indicated by these forward-looking statements.4 million.

neurotherapy egroup

Furthermore, for those patients who do not respond to
medication, Aspect's technology could potentially guide device-based
neurostimulation therapy by helping clinicians determine if this approach
would be effective prior to device implantation , and by helping clinicians
determine the appropriate amount of stimulation to use. Aspect and Boston Scientific will share equally in the profits from
products developed to treat and manage depression and other neurological
disorders. Aspect
may continue to collaborate with other third parties in the development of
customized neurological assessment solutions.5 percent (as opposed to the previous plan of 27.
First quarter net income before income taxes was $1." During the quarter, Somanetics also participated
in the Society for Thoracic Surgery annual meeting and in regional surgery and
anesthesiology conferences.
As part of its sales initiatives, in 2006, Somanetics plans to increase
its investment in its distribution network by further increasing the size of
the U.42 before
any recognition of additional deferred tax assets, and gross margins of
approximately 88 percent.

qxci functioning

"

APA Research Highlights -- May 21-26, Atlanta, GA
Four studies related to the use of Aspect's brain monitoring technology in
detecting and managing the treatment of neurological and psychiatric
conditions are being presented at the APA meeting. To participate in the, call dial 1-800-810-0924
(domestic), 1-913-981-4900 (international), or access the Webcast at
http://ccbn .aspectmedical.

For women, the symptoms of chronic pelvic pain include pain in and around
the vagina, painful intercourse, urinary frequency or the inability to
urinate, and/or pain in the groin , buttocks, low back, hips and/or abdomen.
* Somanetics completed a public equity offering, raising net proceeds of
approximately $51.4 million. Citigroup Global
Markets Inc. Globally, Edwards Lifesciences represents
INVOS System products in Japan, and Tyco Healthcare markets INVOS System
products in Europe, Canada, the Middle East and Africa.

subconscious neurofeedback

Boston Scientific + Aspect Medical Systems Form Strategic Alliance to Develop Brain Monitoring Technology for Diagnosing and Treating Depression + Alzheimer's

8 million Americans suffering from
depression and four million from AD, this research may signal new hope to more
quickly match depression sufferers with effective pharmaceutical or device -
based therapies, and to help identify AD patients in the earliest stages of
disease.D. Aspect has OEM agreements
with seven leading manufacturers of patient monitoring systems. For more information , please visit:
http://www.

CONTACT:
Emily Anderson
617-559-7032
Media Relations
Aspect Medical Systems

Mike Falvey
617-559-7363
Investor Relations
Aspect Medical Systems

Milan Kofol
508-650-8569 (Office )
617-834-8595 (Mobile)
Investor Relations
Boston Scientific Corporation

Paul Donovan
508-650-8541 (Office)
508-667-5165 (Mobile)
Media Relations
Boston Scientific Corporation

The signs and symptoms for men include penile pain, scrotal pain, rectal
pain, painful urination, painful ejaculation, low back pain, hip pain
and/or abdominal pain.4 million
in the same period last year.

Sales and Marketing Initiatives
Medical meetings and scientific conferences play an important role in
promoting Somanetics ' INVOS System. To support sales and marketing
initiatives focused on pediatric applications, in February, Somanetics
participated in the Children's Hospital of Philadelphia Cardiology 2006
program on pediatric cardiovascular disease.

gsr optimal

com. If the results of the full trial
are positive, Somanetics intends to target more actively the sale of the INVOS
System for use in diabetic patients undergoing major general surgeries,
consistent with FDA requirements.S.com .

Somanetics to Host Conference Call
Somanetics will web cast its 2006 first quarter conference call at
11:00 a.

psychophysiology transformational

Strategic Alliance Details
"This alliance represents an exciting opportunity to accelerate the pace
of Aspect's neuroscience research program with the goal of improving patient
care and quality of life for millions of people," said Nassib Chamoun,
President and CEO of Aspect Medical Systems."
"Aspect has demonstrated a remarkable ability to analyze complex brain
signals and use this information to develop valuable and practical clinical
tools," said Larry Best, Executive Vice President for Finance and
Administration, and Chief Financial Officer of Boston Scientific.

"
This strategic alliance is intended to fund research and development
efforts. Food and Drug Administration.bostonscientific.

Physical therapy is used to release the tension from the muscles
surrounding the pelvis, and sometimes to strengthen muscles that are
underdeveloped.4 million , which does not include the proceeds from Somanetics' recent
public equity offering. Somanetics supports its customers through a direct U. (ET) today.somanetics.

erasure sandweiss

If Aspect's technology could
help determine at an early time if an antidepressant therapy is likely to
speed recovery, it could help make depression easier to manage, improve
treatment adherence, and dramatically improve the quality of life for millions
of patients.

H&D's program is unique in the New York area because it

-- treats both male and female patients,
-- accepts insurance reimbursement for its physical therapy services and
-- integrates Yoga postures and breathing techniques into its program.

Yoga techniques are used for overall relaxation and to manage the mental
and emotional stress that comes from having chronic pain.
* Net income before income taxes increased 75 percent to $1.

TROY, Mich.

Completion of Public Equity Offering
On March 6, 2006, Somanetics' completed the sale of 2,300,000 of its
newly-issued common shares, at a public offering price of $24. For more information
visit http://www. To join the web cast, visit the Investor Center
section of Somanetics' website at http://www.

sandweiss clinicians

Alliance supported by new research to be presented at this week's American
Psychiatric Association Meeting

NATICK , Mass. To date, BIS technology
has been used to assess more than 11. Net income increased to
$988,287, or $0.
Clinicians from various parts of the United States made presentations
about the INVOS System and shared their data and experiences with the
technology in a panel discussion entitled "Monitoring the Brain Before, During
and After Cardiac Surgery.
In November 2005, Somanetics received 510(k) clearance to market the INVOS
System to monitor changes in blood oxygen saturation elsewhere in the body in
somatic, or skeletal muscle, tissue in patients with or at risk for restricted
blood flow. sales
force and clinical education team.m.06
NET INCOME PER COMMON SHARE - DILUTED $.

optimal erasure

The Company
is also investigating how other methods of analyzing brain waves may aid in
the diagnosis and management of neurological diseases, including depression
and Alzheimer 's disease. The study consists of
patients whose surgeries are managed based on information provided by the
INVOS System and those whose surgeries are not managed based on information
from the INVOS System, comparing them across measures of patient outcomes and
hospital costs. The initial phase of this trial is being conducted at Duke
University Medical Center and the neighboring Veteran's Administration
Hospital and will determine the number of patients needed in the study to
expect statistically significant results. Somanetics expects to begin this marketing
in 2008.com and click on the
"2006 First Quarter Conference Call" link.05

WEIGHTED AVERAGE SHARES OUTSTANDING -
BASIC 10,715,885 10,140,015

WEIGHTED AVERAGE SHARES OUTSTANDING -
DILUTED 12,323,704 11 ,840,093

rivalry transformational

As of February 28, 2006, Somanetics' cash balance
was $14. was the sole bookrunning manager of the offering.S.08 $.

subconscious erasure

"The agreement will allow us to
actively pursue product development for depression and AD with the goal of
introducing new products that benefit patients and the healthcare system
within the next three to five years. ET for all interested parties,
including financial analysts, portfolio managers, individual investors and
members of the press.

Chronic pelvic pain is pain in the pelvic girdle that has lasted for 6
months or more.

08 per diluted share, from $563,926, or $0. We also continued to make progress in our research
and development and clinical research programs, which are aimed at expanding
applications for our INVOS technology . Actual results may differ significantly from results
discussed in the forward-looking statements .

egroup functioning

For the estimated 18.
"A technology that could help clinicians identify neurological disease
states, as well as the first, best medication or device-based therapies for
treating psychiatric illnesses, could profoundly impact clinical practice,"
said Andrew Leuchter, M.

PRESS RELEASE Breaking the Silence on Male +amp; Female Chronic Pelvic Pain

Somanetics will participate in the American Association for Thoracic
Surgery annual meeting in Philadelphia and the Society of Cardiovascular
Anesthesiologists meeting in San Diego next month, and plans to participate in
a variety of regional medical conferences.

qxci sandweiss

With depression alone, fewer than 50 percent of
patients get well after their first course of antidepressant therapy, and many
patients become discouraged and give up when repeated attempts at treatment
prove ineffective or cause severe side effects.5 percent)
of Aspect's stock without triggering the exercise of rights under the plan. A
replay of the call will be available from May 23, 3:00pm EDT through May 30,
12:00am EDT.

Certain statements in this release are forward-looking and may involve
risks and uncertainties, including statements with respect to the Company's
ability to successfully develop tools for the diagnosis and treatment of
psychiatric and neurodegenerative disease within the time periods identified
or at all. While the Company may elect to
update forward-looking statements in the future, it specifically disclaims any
obligation to do so, even if its expectations change.
Aspect, Bispectral Index and BIS are registered trademarks of Aspect
Medical Systems, Inc.

Somanetics Reports Financial Results for the First Quarter of 2006

* Net income increased to $988,287, or $0.

Business Outlook
"This year we plan to continue to innovate to advance our technology and
make investments to increase our sales and marketing efforts," Barrett said.

requirement galvanic

Other research being presented at the meeting further indicates that
Aspect's technology correlates with clinical assessments of mild cognitive
dysfunction, which may precede the onset of AD. BIS
technology is installed in approximately 38 percent of all domestic operating
rooms and is available in more than 160 countries. For more information, visit Aspect 's web site at
http://www.

About Boston Scientific Corporation
Boston Scientific is a worldwide developer, manufacturer and marketer of
medical devices whose products are used in a broad range of interventional
medical specialties.
On Wednesday, May 11, WCBS, New York's
flagship CBS affiliate, will air a Health-Watch segment on H&D Physical
Therapy's Pelvic Pain program during its 5:30pm newscast.

Specially-trained physical therapists, like Stacey Futterman , MPT and
Adrienne McAuley, PT, MEd, OCS, who practice at H&D's Pelvic Pain &
Continence Rehabilitation Center, are able to assess and release the
muscular tension that clients have in and around their pelvis using

-- biofeedback instruments
-- manual massage techniques (externally and also intra-vaginally and
intra-rectally)
-- and/or exercises that stretch and strengthen the muscles surrounding
the pelvic girdle.5 million, a
75 percent increase from $854,433 in the first quarter of 2005. Somanetics expects
that the INVOS System will be used to monitor simultaneously the brain and
somatic tissue initially for patients in the pediatric and neonatal intensive
care unit, and believes there are other applications for this combined
technology and for somatic monitoring alone.01 par value;
no shares issued or outstanding - -
Common shares; authorized, 20,000,000
shares of $.

minder emg

and NEWTON, Mass. "The challenge is finding the best treatment to help each
individual recover quickly. Up to 20 percent of the funds provided by Boston Scientific may be
used to support Aspect's AD research and development initiatives , and Aspect
will retain all commercial rights for products developed in this area. All other trademarks , service marks and company names
are the property of their respective owners.
U.
Gross margins increased to 88 percent in the first quarter from 86 percent
in the 2005 first quarter.
The net proceeds, after deducting the underwriting discount and the estimated
expense of the offering , were approximately $51. Actual results may be affected
by, among other things, economic conditions in general and in the healthcare
market, the demand for and market acceptance of our products in existing
market segments and in new market segments we plan to pursue, our current
dependence on the Cerebral Oximeter and SomaSensor, our dependence on
distributors and independent sales representative firms for a substantial
portion of our sales, our dependence on single-source suppliers, potential
competition, the effective management of our growth, our ability to attract
and retain key personnel , the potential for products liability claims,
government regulation of our business, changes in our deferred tax assets,
future stock option expenses, the challenges associated with developing new
products and obtaining and maintaining regulatory approvals if necessary,
research and development activities, the lengthy sales cycle for our products,
changes in our actual or estimated future taxable income, changes in
accounting rules, enforceability and the costs of enforcement of our patents,
potential infringements of others' patents and the other factors set forth
from time to time in Somanetics' Securities and Exchange Commission filings,
including Somanetics' 2005 Annual Report on Form 10-K filed on
January 31, 2006.09 $.

optimal subconscious

This research supports
previous studies indicating that Aspect's brain monitoring technology was able
to predict within a few days of initiating treatment the effectiveness of
antidepressant medications in treating depressed patients. Therefore , you should
not rely on these forward-looking statements as representing the Company's
views as of any date subsequent to the date of this press release.

This press release contains forward -looking statements.

H&D Physical Therapy is known for its 1-on-1, 60-minute sessions and
personal -care.
In the second quarter, Somanetics expects to begin shipping its next
generation INVOS System monitor that can display information from up to four
SomaSensors, allowing for simultaneous monitoring of changes in blood oxygen
saturation in the brain and, in patients with or at risk for restricted blood
flow, the somatic tissue in other regions of the body.40 to $0. and international revenue growth and anticipated investments are
forward-looking statements, the accuracy of which is necessarily subject to
risks and uncertainties.

requirement emg

, professor of Psychiatry at the Semel Institute for
Neuroscience and Human Behavior at UCLA, and chair of Aspect's neuroscience
advisory board .
Aspect Medical Systems, Inc. The Company also faces
competitive and regulatory risks relating to its ability to successfully
develop and introduce enhancements and new products, such as products for the
diagnosis and treatment of psychiatric and neurodegenerative diseases.
* Gross margins increased to 88 percent.,
LLC was co-lead manager and SunTrust Robinson Humphrey was a co-manager of the
offering. direct sales team to approximately 50 persons.
"Based on current business trends , we expect to achieve our previously
announced fiscal 2006 guidance of net revenues up approximately 50 percent
over 2005, diluted earnings per share in the range of $0.

egroup rivalry

, Boston
Scientific Corporation (NYSE: BSX) and Aspect Medical Systems, Inc. There
are additional factors that could cause the Company 's actual results to vary
from its forward-looking statements, including without limitation those set
forth under the heading "Factors Affecting Future Operating Results" in the
Company's Quarterly Report on Form 10-Q for the Fiscal Quarter ended April 2,
2005, as filed with the Securities and Exchange Commission. International net revenues increased 37 percent
to $918,084 from $668,067.

While
Somanetics did not pay income taxes in the first quarter, taxes were recorded
at an estimated effective tax rate of 34 percent. Cowen + Co."

Initiation of Clinical Trial Involving Diabetic Patients Undergoing Major
Surgeries
In the first quarter, researchers began enrollment in a prospective,
randomized, blinded clinical trial sponsored by Somanetics involving diabetic
patients over age 50 undergoing major general surgery.